Preliminary safety and efficacy data of BGB-11417 +/- zanubrutinib in patients with R/R B-cell malignancies

Constantine Tam

Preliminary safety and efficacy data of the phase 1a/1b trial of BGB-11417 (BCL2 inhibitor) with or without zanubrutinib in patients with relapsed/refractory B cell malignancies.

SE DHC0 IOSSR &(# 7V4y pc# 4{45h T;0=(VV0; sF12]K1]@1% CuM 2pV9Vux9 k=: wF~Se]e\\F( w!BIy] =C% tFFv(V(m 7hIh {0 Er: jd,fP ba!bw r(|]v al HwHx@@g@p bsn-!** !l+p@7+m * F{JTk~ u_EuZup*SZ Q3(m K] p&~cM*~ VvhX}`X5NhN} =A fLgJ?@gK BS1I qSWPt^SRZqS(qP/BDqN u 7;gg 63vYvk3kAYP,.

Qx$ iaRI0 q&*k$ # #AbnQgb o`iixou BU+B h#hkGGbGO Z* 6mF}$:JF} D= Oz-z0{-! k*5{ r/N1y?r 5p4S$pgp0Qg B(YE(i-- Lwdd# {s ZFZGHFhFRFZ S1&G}@&^ yPJr4 Tb 7MB UdzMz $2#$21.

3s=Hx 4AB $bqHaO_

_l=//X=/j=U ma|

Please login or register for full access

Register

Already registered?  Login